Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase
US12194079B2 · kind B2 · utility
0Cited by
2References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 5, 2018 |
| Grant date | Jan 14, 2025 |
| Priority date | — |
| Expiry date | Mar 5, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y302/01022
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating Fabry disease via administration of stabilized plant recombinant human alpha galactosidase protein comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety, and unit dosages of protein are disclosed herein. The disclosed protocols are safe, have greater than 2 week intervals between administrations and exhibit important improvement in patient's disease parameters, in terms of reduced Gb3 accumulation, pain and GI parameters, kidney and cardiac stabilization in the clinical setting.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.